Alecardio
Effect Of Aleglitazar On Cardiovascular Outcomes After Acute Coronary Syndrome With Type 2 Diabetes Mellitus.
- Alecardio was a Phase III, multi-center, randomized double blind, placebo-controlled trial
- Conducted in 720 hospitals in 26 countries throughout North America, Latin America, Europe and Asia-Pacific regions
- The enrollment of 7,226 patients hospitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetes occurred between February 2010 and May 2012
- Treatment was planned to continue until patients were followed-up for at least 2.5 years and 950 primary end point events were positively adjudicated
